Efficacy and safety of bictegravir plus lenacapavir: 48-week outcomes in virologically suppressed people with HIV-1 on complex antiretroviral regimens at baseline

被引：0
|
作者：
Mounzer, K. [1 ]
Slim, J. [2 ]
Ramgopal, M. [3 ]
Hedgcock, M. [4 ]
Bloch, M. [5 ]
Santana, J. [6 ]
Mendes, I. [7 ]
Zhang, X. [7 ]
Sklar, P. [7 ]
Montezuma-Rusca, J. M. [7 ]
Segal-Maurer, S. [8 ]
机构：
[1] Philadelphia FIGHT, Philadelphia, PA USA
[2] New York Med Coll, Valhalla, NY 10595 USA
[3] Midway Immunol & Res Ctr, Ft Pierce, FL USA
[4] Spectrum Hlth, Vancouver, BC, Canada
[5] Holdsworth House Med Practice, Darlinghurst, NSW, Australia
[6] Univ Puerto Rico, San Juan, PR 00936 USA
[7] Gilead Sci Inc, Foster City, CA 94404 USA
[8] New York Presbyterian Queens, Flushing, NY USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2024年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
OAB2602
引用
收藏
页码：16 / 16
页数：1
相关论文
共 50 条
  • [21] Economic evaluation of nevirapine plus raltegravir as maintenance antiretroviral therapy in virologically suppressed HIV-1 infected patients
    Ravasio, Roberto
    Rigo, Fabio
    Lattuada, Emanuela
    Concia, Ercole
    Lanzafame, Massimiliano
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2016, 3 (02) : 110 - 114
  • [22] Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
    Podzamczer, Daniel
    Imaz, Arkaitz
    Lopez-Lirola, Ana
    Knobel, Hernando
    Masia, Mar
    Fanciulli, Chiara
    Hernandez, Cristina
    Lagarde, Maria
    Gutierrez, Angela
    Curran, Adria
    Morano, Luis
    Montero-Alonso, Marta
    Troya, Jesus
    Rigo, Raul
    Casadella, Maria
    Navarro-Alcaraz, Antonio
    Ardila, Fernando
    Parera, Mariona
    Bernal, Enrique
    Echeverria, Patricia
    Estrada, Vicente
    Hidalgo-Tenorio, Carmen
    Macias, Juan
    Prieto, Paula
    Portilla, Joaquin
    Valencia, Eulalia
    Vivancos, Maria Jesus
    Rivero, Antonio
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (11) : 2696 - 2701
  • [23] ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results
    Murphy, RL
    Brun, S
    Hicks, C
    Eron, JT
    Gulick, R
    King, M
    White, AC
    Benson, C
    Thompson, M
    Kessler, HA
    Hammer, S
    Bertz, R
    Hsu, A
    Japour, A
    Sun, E
    AIDS, 2001, 15 (01) : F1 - F9
  • [24] Dolutegravir/lamivudine efficacy outcomes in people living with HIV with or without resistance results: 48-week pooled analysis
    Scholten, Stefan
    Cahn, Pedro
    Portilla, Joaquin
    Bisshop, Fiona
    Hodder, Sally
    Ruane, Peter
    Kaplan, Richard
    Wynne, Brian
    Man, Choy
    Blair, Elizabeth
    Grove, Richard
    van Wyk, Jean
    Ait-Khaled, Mounir
    Okoli, Chinyere
    HIV MEDICINE, 2022, 23 : 34 - 35
  • [25] Comparability of 48-week efficacy and safety of cabotegravir plus rilpivirine long-acting every 8 weeks to standard of care in suppressed HIV-1-infected patients
    Chounta, V.
    Snedecor, S.
    Wu, S.
    Van de Velde, N.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 23 - 24
  • [26] Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed
    Borghetti, Alberto
    Ciccullo, Arturo
    Lombardi, Francesca
    Giannarelli, Diana
    Passerotto, Rosa Anna
    Lamanna, Francesco
    Carcagni, Antonella
    Farinacci, Damiano
    Dusina, Alex
    Baldin, Gianmaria
    Zazzi, Maurizio
    Di Giambenedetto, Simona
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (05):
  • [27] Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial
    Moyle, Graeme
    Assoumou, Lambert
    de Castro, Nathalie
    Post, Frank A.
    Curran, Adrian
    Rusconi, Stefano
    De Wit, Stephane
    Stephan, Christoph
    Raffi, Francois
    Johnson, Margaret
    Masia, Mar
    Vera, Jaime
    Jones, Bryn
    Grove, Richard
    Fletcher, Carl
    Duffy, Annie
    Morris, Kellie
    Pozniak, Anton
    LANCET HIV, 2024, 11 (03): : e156 - e166
  • [28] Effectiveness, safety and tolerability of dolutegravir/lamivudine versus tenofovir alafenamide/emtricitabine/bictegravir in a real-life cohort of HIV-1 virologically suppressed treatment experienced people living with HIV
    Tordi, S.
    De Socio, G. V.
    Altobelli, D.
    Gidari, A.
    Zoffoli, A.
    Francisci, D.
    HIV MEDICINE, 2023, 24 : 153 - 155
  • [29] Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naive, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety
    Cento, Valeria
    Perno, Carlo Federico
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2020, 20 : 228 - 237
  • [30] Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1:48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
    Daar, Eric S.
    Dejesus, Edwin
    Ruane, Peter
    Crofoot, Gordon
    Oguchi, Godson
    Creticos, Catherine
    Rockstroh, Juergen K.
    Molina, Jean-Michel
    Koenig, Ellen
    Liu, Ya-Pei
    Custodio, Joseph
    Andreatta, Kristen
    Graham, Hiba
    Cheng, Andrew
    Martin, Hal
    Quirk, Erin
    LANCET HIV, 2018, 5 (07): : E347 - E356
12345